Least Convincing Argument of the Day

Here is James Caruso, the chief commercial officer for drug maker Allos, defending the price of cancer drug Foltyn:

Mr. Caruso also said the price of Folotyn was not out of line with that of other drugs for rare cancers. Patients, moreover, are likely to use the drug for only a couple of months because the tumor worsens so quickly, he said.

In other words, our drug isn't so expensive given how poorly it works.